Navigation Links
Stereotaxis Reports First Quarter 2011 Financial Results
Date:5/2/2011

ST. LOUIS, May 2, 2011 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today reported financial results for the first quarter ended March 31, 2011.  First quarter results included continued strong momentum in new capital orders and revenue for the Company's Odyssey™ systems and growth in recurring revenue.  In addition, the Company announced that its new Stereotaxis Epoch™ platform, which enhances the efficiency and versatility of the Niobe system, will be unveiled at the Heart Rhythm Society's (HRS) 32nd Annual Scientific Sessions in San Francisco during May 5-7, 2011.

Revenue for the first quarter 2011 totaled $10.2 million, compared to $10.6 million in the first quarter 2010.  The Company recognized revenue of $1.4 million in Niobe® robotic systems.   As the Company previously announced, installation delays due to production constraints with one of its imaging partners impacted revenue growth during the first quarter 2011.  Odyssey systems revenue in the first quarter totaled $2.7 million, compared to $0.8 million in the first quarter 2010.  Disposables, services and accessories revenue for the quarter ended March 31, 2011 was $5.9 million, up 10.3% from the year-ago quarter.

"The continued strong momentum for Odyssey in the first quarter reflects the growing market demand from both standard and robotic electrophysiology (EP) labs for this unique data integration and clinical networking platform," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.  "We remain focused on establishing our Niobe robotic platform as a new standard of care for EP interventional medicine, and will introduce at the upcoming HRS annual meeting our Stereotaxis Epoch solutions system that we believe dramatically enhances efficiency and versatility of robotic interventional procedures while offering improved safety and efficacy over manual treatments.  In addition, we continue to expect resolution of our imaging partner's supply issue that impacted first quarter installations will be completed in the second quarter 2011."

The Company generated global new capital orders in the first quarter 2011 of $7.1 million, compared to $7.2 million in capital orders placed during the first quarter 2010.  Global orders for the Niobe robotic system in the first quarter 2011 totaled $4.6 million, compared to $5.7 million in Niobe orders reported in the year ago quarter.  Odyssey system orders in the first quarter 2011 were $2.5 million, up 66.7% from the $1.5 million in Odyssey orders in the year ago quarter.  New capital orders from North America were $3.3 million, or 47% of total orders in the first quarter of 2011.  

Product Advancements to be Featured at Heart Rhythm Society's 32nd Annual Scientific SessionsStereotaxis announced that its new Stereotaxis Epoch™ platform, which enhances the efficiency and versatility of the Niobe system, will be unveiled at the Heart Rhythm Society's (HRS) 32nd Annual Scientific Sessions in San Francisco during May 5-7, 2011.  The Stereotaxis Epoch solution is designed to meet the broad range of clinical needs physicians face today and in the future.  Building on the strength of Magnetic Navigation's exceptional safety profile and significant radiation reduction, the Epoch platform features the latest technological breakthroughs in Magnetic Navigation, which will lead to faster, more efficient, and dynamic magnetic catheter control.

"We remain focused on developing solutions that meet the most critical needs of our customers, while supporting any preferred clinical treatment technique.  Epoch is designed to significantly reduce procedure time for all types of robotic-assisted EP procedures, especially for complex ablation procedures.  We believe the Epoch platform will enable a much more efficient and enhanced EP workflow while maintaining our excellent profile in safety, radiation reduction and clinical outcomes," stated Mr. Kaminski.

First Quarter 2011 Financial PerformanceGross margin for the first quarter ended March 31, 2011 was $7.2 million, or 70.6% of net sales.  Gross margin for the year ago quarter was $7.7 million, or 72.5% of net sales.  Operating expenses for first quarter 2011 totaled $16.0 million.  Cash burn for the first quarter of 2011 was $11.0 million.

The operating loss for the first quarter 2011 was $(8.8) million, compared to an operating loss of $(6.3) million for the first quarter 2010.  The net loss for the first quarter 2011 was $(9.5) million, or $(0.17) per share, compared to a net loss of $(8.4) million, or $(0.17) per share, reported for the first quarter 2010.  The weighted average shares for the first quarter of 2011 totaled 54.7 million compared with 49.6 million in the first quarter of 2010.  The increase was due in large part to the issuance of 4.6 million shares as part of the stock offering completed in November 2010.

At March 31, 2011, Stereotaxis had cash and cash equivalents of $30.4 million, compared to $35.2 million on December 31, 2010.  Total debt was $33.5 million, including $17.1 million drawn against the Company's $30 million line of credit.  

2011 Financial OutlookThe Company updated its outlook for 2011 operating expense, and reiterated its outlook for 2011 as follows:

  • New capital order growth expected to be in the mid-30% range
  • Total revenue growth expected to be in the range of 20% to 30%
  • Gross margins expected to be in the high-60% range
  • Operating expenses expected to be in the range of $64 million to $65 million

  • Conference Call InformationStereotaxis will hold a conference call today, May 2, 2011 at 4:30 p.m. Eastern Time, to discuss first quarter results and operational highlights.  The dial-in number for the conference call is 1-877-941-2927 for domestic participants and 1-480-629-9724 for international participants.  An audio replay of the call will be available for seven days following the call, and can be accessed by dialing 1-800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4434733#.  The call will also be available on the Internet live and for 90 days thereafter at www.stereotaxis.com.

    About Stereotaxis   www.stereotaxis.com   www.odysseyexperience.comStereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

    Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

    The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

    This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to,   continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.STEREOTAXIS, INC.BALANCE SHEETS(Unaudited)March 31,2011December 31,2010(Unaudited)AssetsCurrent assets:Cash and cash equivalents

    $
    30,394,919$
    35,248,819Accounts receivable, net of allowance of $377,147 and $367,536 in 2011 and 2010, respectively

    13,216,66613,915,569Current portion of long-term receivables

    30,80030,800Inventories

    6,042,3375,441,475Prepaid expenses and other current assets

    4,390,1714,557,718Total current assets

    54,074,89359,194,381Property and equipment, net

    3,814,9953,840,622Intangible assets

    2,504,0282,578,986Long-term receivables

    111,270109,266Other assets

    43,78938,537Total assets

    $
    ,548,975$
    5,761,792Liabilities and stockholders' equityCurrent liabilities:   Current maturities of long-term debt

    $
    26,499,626$
    20,894,091   Accounts payable

    7,365,0968,796,182   Accrued liabilities

    7,659,1866,966,571   Deferred contract revenue

    6,253,8756,600,313   Warrants

    3,521,4523,541,798Total current liabilities

    51,299,23546,798,955Long-term debt, less current maturities

    7,000,0008,000,000Long-term deferred contract revenue

    408,881478,850Other liabilities

    5,9728,741Stockholders' equity:Preferred stock, par value $0.001; 10,000,000 shares authorized   at 2011 and 2010; none outstanding at 2011 and 2010

    --Common stock, par value $0.001; 100,000,000 shares authorized at   2011 and 2010; 55,326,172 and 54,746,240 issued at 2011   and 2010, respectively

    55,32654,746Additional paid-in capital

    354,911,764354,002,770Treasury stock, 40,151 shares at 2010 and 2009

    (205,999)(205,999)Accumulated deficit

    (352,926,204)(343,376,271)Total stockholders' equity

    1,834,88710,475,246Total liabilities and stockholders' equity

    $
    ,548,975$
    5,761,792STEREOTAXIS, INC.STATEMENTS OF OPERATIONS(Unaudited)Three Months Ended

    March 31,20112010Revenue   System

    $
    4,288,176$
    5,233,755   Disposables, service and accessories

    5,936,5285,382,854Total revenue

    10,224,70410,616,609Cost of revenue   System

    2,184,4782,076,717   Disposables, service and accessories

    820,501843,953Total cost of revenue

    3,004,9792,920,670Gross margin

    7,219,7257,695,939Operating expenses:Research and development

    3,394,2593,369,538Sales and marketing

    8,338,3366,695,117General and administration

    4,250,2693,890,336Total operating expenses

    15,982,86413,954,991Operating loss

    (8,763,139)(6,259,052)Other income/(expense)

    20,346(1,537,169)Interest income

    3,1872,782Interest expense

    (810,327)(633,118)Net loss

    $
    (9,549,933)$
    (8,426,557)Net loss per common share:   Basic and diluted

    $
    (0.17)$
    (0.17)Weighted average shares used in computing net   loss per common share: Basic and diluted

    54,719,67749,621,318
    '/>"/>

    SOURCE Stereotaxis, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Stereotaxis Introduces New Electrophysiology Platform: Epoch™
    2. Stereotaxis to Present at Upcoming Investor Conferences
    3. Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook
    4. Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension
    5. Stereotaxis to Report Fourth Quarter and Full Year 2010 Financial Results and Conduct Conference Call on February 28, 2011
    6. Stereotaxis Announces CE Mark and First Human Case for Vdrive™
    7. Stereotaxis Announces Expansion of Catheter Strategic Partnership
    8. Stereotaxis Announces Global Initial Training Site at University of Chicago
    9. Stereotaxis Completes $40 Million Credit Facility
    10. Stereotaxis Announces Public Offering of Common Stock
    11. Stereotaxis Receives Commitment to Increase and Extend Credit Facility
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
    (Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
    (Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
    Breaking Medicine Technology:
    (Date:5/26/2016)... ... May 26, 2016 , ... ... the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm ... Dr. Maisel, founder of Retina Group of New York , is a ...
    (Date:5/26/2016)... Los Angeles, CA (PRWEB) , ... May 26, 2016 , ... In an effort to ... Snapchat videos available to both Snapchat users and those who do not use the app. ... available on his new page, Dr. Mohebi Live . , Dr. Mohebi says, ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life Science Logistics ... organization has earned its ISO 13485 certification, indicating the company’s quality control system ... and policies associated with ISO quality standard 13485. , BSI Group America, ...
    (Date:5/26/2016)... ... May 26, 2016 , ... The Lung Institute ... a six-week smoking cessation class starting June 6 at their clinic in downtown Tampa. ... . , Additionally, the Lung Institute has created a free downloadable 4 Week ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at East ... practices, arts & crafts, discussions, and games all geared towards enhancing your child’s ... combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga training. ...
    Breaking Medicine News(10 mins):